Myqorzo sales surged 427.1% quarter-over-quarter to $25.3 million in Q2, outperforming Bristol Myers Squibb's Camzyos in treating symptomatic nonobstructive HCM, according to Phase 3 data. Cytokinetics reported a 47.8% revenue increase to $28.6 million and a better-than-expected non-GAAP EPS of -$1.5. However, safety concerns arose with 10.5% of patients experiencing reversible LVEF reductions on aficamten versus 0.8% on placebo. The current risk/reward profile for Cytokinetics appears balanced amid competitive and safety challenges.
Cytokinetics (CYTK) shares are priced at USD 73.76 on Pluang as of Sep 14, 2026 20:22 WIB, showing a minimal 1-day change of -0.01%. The stock's market cap stands at $10.25 billion, reflecting its significant presence in the technology sector. Despite recent revenue growth and product performance, the share price remains below its 52-week high of $87.26, indicating cautious investor sentiment.
Cytokinetics, a biopharmaceutical company specializing in cardiovascular treatments, will announce its third quarter 2026 financial results on November 4. Following the release, senior management will hold a conference call to discuss the results and...
An executive at Cytokinetics sold 3,500 shares worth about $224,035 as the company's heart disease drug Myqorzo expands in the U.S. and gains approvals in Canada, Germany, and the U.K. Myqorzo has strong prescription growth, accounting for over 40% o...
Cytokinetics, a cardiovascular biopharmaceutical company, granted stock options for 60,465 shares and 40,084 restricted stock units (RSUs) to 29 new employees hired in September and October 2026. The RSUs vest over three years, while the stock option...
Health Canada has approved MYQORZO (aficamten) for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) classified as NYHA class II-III. MYQORZO is an oral drug that reduces heart muscle contractility and obstruction, impro...
